1. CHU Clermont-Ferrand, Service d’Hématologie Clinique Adulte et de Thérapie Cellulaire, and
2. Université d’Auvergne, Clermont-Ferrand, France;
3. Division of Hematologic Neoplasia, Dana-Farber Cancer Institute, Boston, MA;
4. Cancer Program, Broad Institute, Cambridge, MA; and
5. Division of Medical Oncology, Dana-Farber Cancer Institute, Brigham and Women’s Hospital and Harvard Medical School, Boston, MA